Authors
Latest:
New Therapies Expand Options in Recurrent Small Cell Lung CancerAriel Lopez-Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have progressed after first-line chemotherapy.
Latest:
Liver Cancer Awareness Month: A Decade of Progress and Hope in Hepatocellular CarcinomaMahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.
Latest:
Exploring Adjuvant Endocrine Therapy in the Breast Cancer SettingTerry P. Mamounas, MD, MPH, discusses the use of extended adjuvant therapy for patients with breast cancer and how the landscape is evolving.
Latest:
Behind the Development of Ivaltinostat in Metastatic PDACMohamad Adham Salkeni, MD, FRCPC, discusses the mechanism of action of ivaltinostat and what rationalizes its use in combination with capecitabine for patients with metastatic pancreatic adenocarcinoma.
Latest:
Future Directions for CAR T-Cell Therapies in Solid TumorsMichael Hurwitz, MD, PhD, discusses the advances being made for the treatment of chimeric antigen receptor T-cell therapies and next steps for evaluating the agent across solid tumors.
Latest:
Immune Checkpoint Inhibitors Offer New Approaches in Head and Neck CancerJoseph M. Curry, MD, discusses the introduction of immune checkpoint inhibitors for the treatment of patients with head and neck cancers.
Latest:
Atezolizumab/Bevacizumab Benefit Potentially Extends to Child-Pugh B HCCStacey Stein, MD, discusses the patient population and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma.
Latest:
Building a Patient-Centered Ecosystem Leads to Better CareWithin the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Latest:
Cervical Cancer Awareness Month: Trials Assess New ImmunotherapiesMargarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists & Research Institute, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.
Latest:
Factors Correlating With Survival in Polycythemia VeraCarole Miller, MD, discusses notable factors which correlated with survival for patients with polycythemia vera in the REVEAL study.
Latest:
Jacob Discusses Bladder Preservation as Top Refusal Reason in SunRISe-1Joseph M. Jacob, MD, discusses the key takeaways from the SunRISe-1 study and data presented at the 2024 Genitourinary Cancers Symposium.
Latest:
Post–COVID-19 Infection Remains a Concern in Patients With CancerMany questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.
Latest:
Miller Discusses Novel Targets in Endometrial CancerEirwen M. Miller, MD, discusses novel biomarkers that she believes will be important for endometrial cancer in the future.
Latest:
Next Steps in Study of PPAR-α Inhibitor Plus Nivolumab in RCCBruno R. Bastos, MD, discusses the future following a study assessing the changes among patients with renal cell carcinoma who were treated with nivolumab and TPST-1120.
Latest:
Social Determinants of Health Impacting Oncology TodayIn season 4, episode 11 of Targeted Talks, Krisda Chaiyachati, MD, MPH, MSHP, discusses the social determinants of health for patients with cancer and key challenges for patients, like transportation insecurity.
Latest:
Recently Introduced Low-Intensity Options for Older Patients With AMLTapan Kadia, MD, discusses the recent and upcoming changes in treatment of acute myeloid leukemia for patients who are not candidates for intensive remission induction therapy.
Latest:
Analyzing Outcomes of Immune Checkpoint Blockade Plus Chemo in SCLCAshish Saxena, MD, explains the outcomes of the addition of immune checkpoint blockade to standard chemotherapy for patients with metastatic small cell lung cancer.
Latest:
The New Algorithm for Second-Line Large B-Cell Lymphoma TreatmentThe diffuse large B-cell lymphoma treatment landscape is evolving with Pola-R-CHP and CAR T-cell therapy moving into the frontline setting.
Latest:
Upfront Nivolumab/Chemo Produces Durable Responses in Urothelial CarcinomaMichiel S. Van der Heijden, MD, PhD, discusses the methods, design, and findings of the phase 3 CheckMate 901 trial of concurrent frontline nivolumab and chemotherapy followed by nivolumab maintenance therapy in urothelial carcinoma.
Latest:
Addressing the Mechanism of Action for the AKT Pathway in TNBCRebecca Dent, MD, discusses how investigators are targeting pathways in patients with triple negative breast cancer.
Latest:
Treating the Patient With CML Who Is Pregnant or Trying to Become PregnantCareful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.
Latest:
Breaking New Ground in Synovial Sarcoma: Choy on the FDA Approval of Afami-celIn this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.
Latest:
Bridging Science and Compassion in Cancer CareIn the second episode of Emerging Experts, Hemali Batra-Sharma, MD, discusses her passion for oncology and some of the experiences that have helped to shape her career.
Latest:
Early Detection & the Right Treatment Critical for Prostate CancerJohn E. Sylvester, MD, a radiation oncologist with GenesisCare, reviews the importance of treating prostate cancer at the earliest stage possible.
Latest:
Treatment Delays in Multiple Myeloma Highlight Racial and Age DisparitiesHamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical practice and patient outcomes.
Latest:
Expanding Treatment Options in Urothelial Cancer With ADCsScott T. Tagawa, MD, MS, FACP, FASCO, discusses the potential benefits of antibody-drug conjugates in urothelial cancer while acknowledging the need for more education and experience among physicians to optimize their use.
Latest:
Addressing Dosing Methods With Teclistamab in Multiple MyelomaEmma Searle, PhD, discusses the dosing approach of the MajestTEC-2 trial (NCT04722146) and sequencing teclistamab (Tecvayli) in patients with multiple myeloma.
Latest:
Durvalumab After Chemotherapy Helps Manage Toxicities in NSCLC TreatmentChemotherapy for the treatment of non-small cell lung cancer can be quite toxic, however, durvalumab after chemotherapy can help manage toxicities while improving overall survival, according to the PACFIC trial.
